Daiichi Sankyo Europe Gmbh

Amgen Inc.

U3 Pharma Gmbh

Daiichi Sankyo Company, Limited

Other

Vivoryon Therapeutics N.v.

Thore Hettmann

Daniel Freeman

Robert Radinsky

Mike Rothe

Reimar Abraham

Esther Zwick-Wallasch

Sabine Blum

Suguru Ueno

Deric L Wheeler

Orit Foord

Stephen D Gillies

Eric Borges

Jens Ruhe

Peter Wirtz

Kerstin Selle

Martin Kleinschmidt

Jens-Ulrich Rahfeld

Norbert Prenzel

Jens Niewöhner

Stefan Schilling

Daniel J Freeman

Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.

Material and methods for treating or preventing HER-3 associated diseases

The invention relates to humanized and de-immunized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Aβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of monoclonal antibodies of the invention to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Aβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the antibodies of the invention.

Humanized and de-immunized antibodies

The present invention relates to the use of an inhibitor of HER-3 for the treatment of a hyperproliferative disease in combination with radiation treatment.

HER3 inhibitor for modulating radiosensitivity

To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; or -L-L-L- (the anti-HER3 antibody is connected to the terminal of L, the antitumor compound is connected to the carbonyl group of &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety or the C terminal of L, with the nitrogen atom of the amino group at position 1 as a connecting position). 

Anti-HER3 antibody-drug conjugate

The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.

AXL antibodies

Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.

Heparin-binding epidermal growth factor-like growth factor binding proteins

Growing community of inventors

Munich, Germany

Thore Hettmann